Although early treatment with intravenous immunoglobulin reduces the risk of coronary artery aneurysms, in refractory cases of Kawasaki disease, myocardial infarction can result from thrombosis of coronary artery aneurysms. Early recognition of myocardial infarction from Kawasaki disease myocarditis can reduce morbidity and mortality. This report describes successful treatment of myocardial infarction from coronary thrombosis in an infant with Kawasaki disease using intravenous tissue plasminogen activator and abciximab.
NewburgerJWTakahashiMGerberMA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-2771.
2.
KatoHIchinoseEKawasakiT. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr. 1986;108:923-927.
3.
McCrindleBWLiJSMinichLL; Pediatric Heart Network Investigators. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007;116:174-179.
4.
NewburgerJWTakahashiMBurnsJC. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347.
5.
PrintzBFSleeperLANewburgerJW. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 2011;57:86-92.
6.
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet. 1994;343:311-222.
7.
MonaglePChalmersEChanA; American College of Chest Physicians. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):887S-968S.
8.
HorigomeHSekijimaTMiyamotoT. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease. Heart. 1997;78:517-518.
9.
TsubataSIchidaFHamamichiYMiyazakiAHashimotoIOkadaT. Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease. Pediatr Cardiol. 1995;16:186-189.
10.
NakagawaMWatanabeNOkunoMOkamotoNFujinoH. Effects of intracoronary tissue-type plasminogen activator treatment in Kawasaki disease and acute myocardial infarction. Cardiology. 2000;94:52-57.
11.
IbbotsonTMcGavinJKGoaKL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63:1121-1163.
12.
IsraelsSJMichelsonAD. Antiplatelet therapy in children. Thromb Res. 2006;118:75-83.
13.
JenningsLKMichelsonADJacoskiMV. Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. Platelets. 2012;23:430-438.
14.
LincoffAMKereiakesDJMascelliMA. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
15.
SivakumarKPavithranS. Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease. Pediatr Cardiol. 2013;34:444-446.
16.
WilliamsRVWilkeVMTaniLYMinichLL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?Pediatrics. 2002;109:E4.
